SCHEMBL426691

SCHEMBL426691

CN(C(=O)n1ccc(-c2cccnc2)n1)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FYN P06241 2/20 0.43
SCN4A P35499 1/20 0.43
KDM4E B2RXH2 3/20 0.40
KMT2A Q03164 1/20 0.40
NPC1 O15118 1/20 0.40
ALOX15 P16050 1/20 0.40
RAB9A P51151 1/20 0.40
CYP11B1 P15538 1/20 0.39
CYP11B2 P19099 1/20 0.39
EGFR P00533 1/20 0.39
PRKCA P17252 1/20 0.39
ALDH1A1 P00352 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
CYP19A1 P11511 1/20 0.39
HTT P42858 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
ABL1 P00519 1/20 0.38
BCR P11274 1/20 0.38
MAPT P10636 1/20 0.38
MKNK1 Q9BUB5 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL426663 0.89 SCN4A (0.48) SCN4AKDM4EKMT2ANPC1RAB9A
SCHEMBL427262 0.87 SCN4A (0.49) SCN4AKDM4EKMT2ANPC1RAB9A
SCHEMBL2181609 0.79 SCN4A (0.62) SCN4AKDM4EKMT2ANPC1RAB9A
SCHEMBL27843224 0.77 CYP2A6 (0.47) FYNKDM4EALOX15ALDH1A1CYP19A1
SCHEMBL426080 0.76 FAAH (0.52) FYNKDM4EKMT2ANPC1ALOX15
SCHEMBL425530 0.70 ELANE (0.47) KDM4EKMT2AALOX15ALDH1A1SMN1; SMN2
SCHEMBL7901000 0.69 SCN4A (0.43) SCN4AKDM4EKMT2ANPC1RAB9A
SCHEMBL9384083 0.69 KMT2A (0.62) FYNKDM4EKMT2AALOX15ALDH1A1
SCHEMBL24937768 0.69 SMN1; SMN2 (0.46) KDM4EKMT2AL3MBTL1SMN1; SMN2
SCHEMBL21634194 0.68 CYP2A6 (0.50) FYNKDM4ENPC1ALOX15RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
WO-2010074588-A2 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2010-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS FAAH, FAAH2, ASAH1 FYN 2251/4885SCN4A 2103/4885KDM4E 1982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.